MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-31-2026
ENDRA Life Sciences Total Current Liabilities 2011-2026 | NDRA
Annual Total Current Liabilities ENDRA Life Sciences
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 751 K | 605 K | 903 K | 1.7 M | 1.54 M | 987 K | 2.07 M | 975 K | 848 K | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 2.07 M | 605 K | 1.15 M |
Total Current Liabilities of other stocks in the Diagnostics research industry
| Issuer | Total Current Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Agilent Technologies
A
|
1.71 B | $ 117.5 | 2.1 % | $ 35.7 B |  USA |
 |
Check-Cap Ltd.
CHEK
|
1.81 M | - | - | $ 9.42 M |  Israel |
 |
Aspira Women's Health
AWH
|
3.46 M | - | -6.19 % | $ 10.5 M | USA |
 |
Biocept
BIOC
|
5.51 M | - | -13.05 % | $ 7.29 M | USA |
 |
Chembio Diagnostics
CEMI
|
39.3 M | - | 0.22 % | $ 16.8 M | USA |
 |
DermTech
DMTK
|
13.4 M | - | -11.32 % | $ 2.94 M | USA |
 |
CareDx, Inc
CDNA
|
89.8 M | $ 16.83 | 4.86 % | $ 897 M | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
13.8 M | - | - | $ 562 M |  Britain |
 |
Exact Sciences Corporation
EXAS
|
641 M | - | - | $ 19.8 B | USA |
 |
Akumin
AKU
|
169 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Enzo Biochem
ENZ
|
24.8 M | - | -8.98 % | $ 14.8 K | USA |
 |
Co-Diagnostics
CODX
|
3.54 M | $ 1.45 | 5.84 % | $ 1.93 M | USA |
 |
Accelerate Diagnostics
AXDX
|
66.6 M | - | -61.36 % | $ 2.46 M | USA |
 |
Castle Biosciences
CSTL
|
49.4 M | $ 23.53 | 1.73 % | $ 654 M | USA |
 |
Global Cord Blood Corporation
CO
|
647 M | - | - | $ 399 M |  China |
 |
Fluidigm Corporation
FLDM
|
54.2 M | - | 1.08 % | $ 308 M | USA |
 |
Charles River Laboratories International
CRL
|
1.12 B | $ 178.34 | 1.53 % | $ 8.84 B | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
1.27 B | - | - | $ 10.7 B | USA |
 |
Interpace Biosciences
IDXG
|
5.1 M | $ 2.2 | -4.35 % | $ 9.73 M | USA |
 |
Danaher Corporation
DHR
|
6.81 B | $ 195.87 | 3.3 % | $ 140 B | USA |
 |
Heska Corporation
HSKA
|
39.6 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
8.27 M | - | -20.0 % | $ 1.06 M | USA |
 |
Illumina
ILMN
|
1.55 B | $ 126.96 | 4.99 % | $ 20.2 B | USA |
 |
Fulgent Genetics
FLGT
|
72.9 M | $ 15.3 | 6.03 % | $ 463 M | USA |
 |
Guardant Health
GH
|
303 M | $ 82.21 | 4.59 % | $ 10.3 B | USA |
 |
QIAGEN N.V.
QGEN
|
512 M | - | - | $ 10.6 B |  Niderland |
 |
Anixa Biosciences
ANIX
|
1.97 M | $ 2.85 | 5.95 % | $ 92.5 K | USA |
 |
Medpace Holdings
MEDP
|
1.34 B | $ 501.23 | 1.56 % | $ 14.5 B | USA |
 |
Biomerica
BMRA
|
1.74 M | $ 2.08 | -2.8 % | $ 4.78 M | USA |
 |
ICON Public Limited Company
ICLR
|
2.8 B | $ 110.37 | 3.33 % | $ 9.1 B |  Irlanda |
 |
Laboratory Corporation of America Holdings
LH
|
2.82 B | $ 264.18 | 1.25 % | $ 22 B | USA |
 |
Celcuity
CELC
|
44.2 M | $ 120.4 | 2.78 % | $ 5.63 B | USA |
 |
Myriad Genetics
MYGN
|
134 M | $ 4.59 | 5.52 % | $ 425 M | USA |
 |
NeoGenomics
NEO
|
88.3 M | $ 8.0 | 4.03 % | $ 1.02 B | USA |
 |
Neogen Corporation
NEOG
|
174 M | $ 9.14 | -2.97 % | $ 1.98 B | USA |
 |
Lantheus Holdings
LNTH
|
333 M | $ 81.67 | 1.34 % | $ 5.51 B | USA |
 |
Motus GI Holdings
MOTS
|
3.27 M | - | -34.28 % | $ 263 K | Israel |
 |
Natera
NTRA
|
310 M | $ 201.9 | 4.6 % | $ 19.9 B | USA |
 |
Invitae Corporation
NVTA
|
108 M | - | - | $ 21.2 M | USA |
 |
Quest Diagnostics Incorporated
DGX
|
2.28 B | $ 192.91 | 0.73 % | $ 21.4 B | USA |
 |
National Research Corporation
NRC
|
36.6 M | $ 16.82 | 2.03 % | $ 376 M | USA |
 |
Organovo Holdings
ONVO
|
3.74 M | - | -2.3 % | $ 19.4 M | USA |
 |
OpGen
OPGN
|
634 K | - | -16.95 % | $ 1.54 M | USA |
 |
Pacific Biosciences of California
PACB
|
72.8 M | $ 1.45 | 8.21 % | $ 435 M | USA |
 |
Psychemedics Corporation
PMD
|
4.71 M | - | -1.84 % | $ 15.3 M | USA |